var data={"title":"Smallpox vaccine (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Smallpox vaccine (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6959?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-patient-drug-information\" class=\"drug drug_patient\">see &quot;Smallpox vaccine (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709414\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Myopericarditis, pericarditis: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Suspected cases of myocarditis and/or pericarditis have been observed in healthy adult primary vaccinees (at an approximate rate of 5.7 per 1000, 95% CI: 1.9 to 13.3) receiving smallpox vaccine.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other serious adverse reactions: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including Stevens Johnson Syndrome), eczema vaccinatum resulting in permanent sequelae or death, ocular complications, blindness, and fetal death have occurred following either primary vaccination or revaccination with live vaccinia virus smallpox vaccines. </p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">These risks are increased in vaccinees with the following conditions and may result in severe disability, permanent neurological sequelae and/or death:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Cardiac disease or a history of cardiac disease</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Eye disease treated with topical steroids</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Congenital or acquired immune deficiency disorders, including those taking immunosuppressive medications </p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Eczema and persons with a history of eczema or other acute or chronic exfoliative skin conditions</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Infants less than 12 months of age </p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Pregnancy</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Transmission of virus:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Smallpox vaccine is a live vaccinia virus that can be transmitted to persons who have close contact with the vaccinee and the risks in contacts are the same as those for the vaccinee. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The risk for experiencing serious vaccination complications must be weighed against the risks for experiencing a potentially fatal smallpox infection.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221461\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ACAM2000</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221473\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Live (Viral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221463\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Primary vaccination and revaccination:</b> Percutaneous: Not for IM,  intradermal, IV, or SubQ injection: Vaccination by scarification (multiple-puncture technique) only: <b>Note:</b> A trace of blood should appear at vaccination site after 15 to 20 seconds; if no trace of blood is visible, an additional 3 insertions should be made using the same needle, without reinserting the needle into the vaccine bottle.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Use a single drop of vaccine suspension and 15 needle punctures (using the same bifurcated needle) into the superficial skin; if the patient does not have a major cutaneous reaction after the first dose (by day 6 to 8), a second dose (revaccination) from another vial or vaccine lot may be administered.  If there is not a reaction to the second dose, consult the CDC or the state or local health department for further guidance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> According to the manufacturer, revaccination is recommended every 3 years for patients at a continued high risk for smallpox infection. The ACIP recommends routine nonemergency revaccination every 3 to 10 years, depending on type of exposure (ACIP [Petersen 2016]). Additional information can be obtained from the Department of Defense and the CDC. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990104\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987393\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221470\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Primary vaccination and revaccination:</b> Children and Adolescents &lt;16 years (in emergency conditions only) and Adolescents &ge;16 years: Percutaneous: Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51160184\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51160185\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062221\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221445\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution [purified monkey cell source]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ACAM2000: 1-5 x 10<sup>8</sup> plaque-forming units per mL [contains polymyxin B, neomycin (trace amounts) and human albumin; packed with diluent, tuberculin syringes for reconstitution, and 100 bifurcated needles for administration]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221432\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234330\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Smallpox vaccine is not available for general public use. Supplies are owned by the US federal government and are included in the Strategic National Stockpile. In August 2007, the FDA licensed the present ACAM2000 formulation of smallpox vaccine. This approval allows the vaccine to be distributed and administered in the event of a smallpox release. Most of the current vaccinations are administered by the US military. Additionally, laboratory workers who may be at risk of exposure may require vaccination. Bioterrorism experts have proposed immunization of first responders (including police, fire, and emergency workers), but these plans have not yet been implemented. Additional information from the CDC is available at <a target=\"_blank\" href=\"https://www.cdc.gov/laboratory/drugservice/formulary.html&amp;token=8fUMx+fB4trlY8x/Mo8Y9Ddj5kItZ1H7qlW/e3GJptY28xGubTU0DXWzUi5nl8+CwNhzfAcY95p7Mq5fGdd6Fg==&amp;TOPIC_ID=10175\" target=\"_blank\">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874989\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142576.pdf&amp;token=gn7alXChC+O1BUcaJOKpa8QBUqKLE2p+JmbrOjQlxu0coEK+kohA/ze8wJyFSZvJk2BlPVwZ17xDFvwgMv4IaLTNgn1YIwQifTNrSFa9pHJKW1QRVkA+Irj8iN4ivzte&amp;TOPIC_ID=10175\" target=\"_blank\">http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142576.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221447\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Vaccination should only be performed by health care providers trained in the safe and efficacious administration of the smallpox vaccine via the percutaneous route. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vaccination by scarification (multiple-puncture technique) only: Administer by percutaneous injection only; not for IM, intradermal, IV, or subcutaneous injection. If alcohol is used to clean the skin, allow site to dry completely prior to administration to prevent the inactivation of the vaccine by the alcohol. A single-use bifurcated needle should be dipped carefully into the reconstituted vaccine (following removal of rubber stopper). Visually confirm that the needle picks up a drop of vaccine solution. Using a bifurcated needle, 1 drop of vaccine is introduced into the superficial layers of the skin using a multiple-puncture technique. The skin over the insertion of the deltoid muscle is the preferred site for vaccination. Deposit the drop of vaccine onto clean, dry skin at the vaccination site. Holding the bifurcated needle perpendicular to the skin, punctures are to be made rapidly within a diameter of about 5 mm into the superficial skin of the vaccination site. The puncture strokes should be vigorous enough to allow a trace of blood to appear after approximately 15 to 20 seconds. Wipe off any remaining vaccine with dry sterile gauze. Dispose of all materials in a biohazard waste container; do not reuse the bifurcated needle. All materials must be burned, boiled, or autoclaved.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">To prevent transmission of the virus, avoid scratching the vaccination site and cover with gauze (using first aid adhesive tape to keep gauze in place); cover gauze with a semipermeable barrier (eg, semiocclusive dressing) or clothing. Ointment or salves should not be applied to the vaccination site. Good handwashing prevents inadvertent inoculation. Vaccinees should change bandages away from others and launder their own linens separately to prevent transmission.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221446\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Smallpox disease prevention:</b> Active immunization against smallpox disease in persons determined to be at high risk for smallpox infection. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following (ACIP [Petersen 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laboratory workers who directly handle cultures or animals who are contaminated or infected with replication-competent vaccinia virus, recombinant vaccinia viruses derived from replication-competent vaccinia strainsor related orthopoxviruses capable of causing infections in humans (eg, monkeypox, cowpox, variola). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Consideration may also be given for vaccination of health care personnel who currently treat or anticipate treating patients with vaccinia virus infections or whose contact is limited to contaminated materials or administering ACAM2000 smallpox vaccine; adherence to appropriate infection prevention measures is also necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In a pre-event vaccination program, the ACIP recommends vaccination for the following (CDC/ACIP [Wharton 2003):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons designated by authorities (smallpox response teams) to investigate and follow-up on initial smallpox cases with the likelihood of direct patient contact</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hospital based health care teams who provide patient care for smallpox patients. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons responsible for administering smallpox vaccine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For post-event vaccination, the ACIP recommends vaccination for the following (CDC [Petersen 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons directly exposed to an accidental or intentional release of the virus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Household family members of a patient with confirmed, probable or suspected smallpox or others spending &ge;3 hours in the household since the onset of fever</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nonhousehold members with &ge;3 hours of  close contact (&lt;6.5 feet or &lt;2 meters) with a confirmed or suspected smallpox patient with a rash. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons considered at high risk for smallpox infection (including healthcare workers) as defined by public health authorities </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221437\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Lymph node pain (19% to 57%), headache (32% to 51%), fatigue (34% to 48%), malaise (28% to 37%), feeling hot (20% to 32%), rigors (12% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Injection site pruritus (82% to 92%), erythema (18% to 24%), skin rash (6% to 11%; includes erythematous rash, folliculitis, nonspecific rash, papulovesicular rash, urticaria)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (10% to 19%), diarrhea (12% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Erythema at injection site (61% to 74%), pain at injection site (37% to 67%), swelling at injection site (28% to 48%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (27% to 46%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Decreased exercise tolerance (8% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (6%), vomiting (3% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphadenopathy (6% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiomyopathy (nonischemic/dilated), ischemic heart disease, myocarditis, pericarditis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Bell's palsy, brain disease, dizziness, encephalitis, Guillain-Barre syndrome, meningitis, paresthesia, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Contact dermatitis, eczema (vaccinatum), erythema multiforme, Stevens-Johnson syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, toothache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Secondary infection (including autoinoculation to eyelid, face, genitalia, lips, mouth, nose, rectum), vaccinia (includes generalized, ocular, progressive, skin infection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Myelitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blindness, corneal injury (scarring), keratitis, photophobia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221450\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Manufacturer labeling: Severe immune deficiency (eg, persons undergoing bone marrow transplant, individuals with primary or acquired immunodeficiency requiring isolation). There are very few absolute contraindications regarding vaccination of individuals at high-risk for exposure to smallpox. The decision to vaccinate must be based on a careful analysis of potential benefits and possible risks.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">ACIP contraindications in a pre-event vaccination program: Serious hypersensitivity to the vaccine or any component of the formulation; history or presence of atopic dermatitis, eczema or other acute, chronic or exfoliative skin conditions (or persons with household contacts with these conditions); immunosuppression (or persons with household contacts who are immunosuppressed); pregnant or breast-feeding women (or household contacts of pregnant women); infants &lt;1 year of age (CDC/ACIP [Wharton 2003])</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">ACIP contraindications for non-emergent use in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses, see guidelines for details (ACIP [Petersen 2015]):</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">\n      <i>Primary vaccines, revaccinees, and household contacts:</i> History or presence of atopic dermatitis, other active exfoliative skin conditions, immunosuppression, pregnancy, and infants</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">\n      <i>Additional contraindications for primary vaccinees and revaccinees:</i>  Breast-feeding, serious vaccine component allergy, and known underlying heart disease.</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">\n      <i>Additional contraindications for primary vaccines only:</i>  3 or more major cardiac risk factors </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">ACIP contraindications in a post-event situation: There are no absolute contraindications to vaccination  (CDC/ACIP [Rotz 2001]; CDC [Petersen 2015]). The following are relative contraindications:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">- Severe immunodeficiency including the following:  bone marrow transplant transplantation within the previous 4 months, HIV infection with CD4 &lt;50 cells/mm<sup>3</sup> (or AIDS-defining condition if recent CD4 count is unavailable; see guideline for pediatric age specific criteria),  severe combined immunodeficiency, complete DiGeorge syndrome, or other severely immunocompromised states requiring isolation (CDC [Petersen 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">- High risk for smallpox infection but without known exposure:  Hypersensitivity to the vaccine or any component of the formulation, atopic dermatitis, solid organ transplantation within the previous 3 months, bone marrow transplant transplantation within the previous 4 to 24 months, HIV infection with CD4 &lt;50 to 199 cells/mm<sup>3</sup> (see guideline for pediatric age specific criteria), active graft-versus-host disease after transplantation, immunosuppressive therapy, or other immunocompromised state (CDC [Petersen 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221435\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Encephalitis:<b> [US Boxed Warning]: Following vaccination, encephalitis, encephalomyelitis, and encephalopathy have been observed.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopericarditis:<b> [US Boxed Warning]: Following vaccination, acute myocarditis and/or pericarditis have been observed.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular complications: <b>[US Boxed Warning]: Following vaccination, ocular complications, including blindness, have occurred. Patients with eye diseases requiring treatment with ophthalmic corticosteroids may be at increased risk for adverse reactions. </b>Following vaccination, accidental infection of the eye may occur (due to touching or rubbing of the eye) resulting in keratitis, corneal scarring, and blindness. Patients using ophthalmic steroids may be at an increased risk for ocular vaccinia. In a nonemergency situation, the ACIP recommends deferring vaccination in persons with an eye condition requiring steroid treatment until the condition resolves and treatment is complete (CDC/ACIP [Wharton 2003]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin and systemic reactions:<b> [US Boxed Warning]: Following vaccination, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, and erythema multiforme major (including Stevens-Johnson syndrome) have been observed.</b> Contact the CDC (770-488-7100) regarding availability and the use of vaccinia immune globulin (VIG) for treatment of vaccinia. Cidofovir is also available (off-label use).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes of vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease:<b> [US Boxed Warning]: Patients with or with a history of cardiovascular disease and patients at risk for cardiovascular disease (eg, hypertension, hyperlipidemia, diabetes, family history, cigarette smoker) may be at an increased risk for severe adverse reactions.</b> Persons with cardiac disease include those with a previous MI, angina, heart failure, cardiomyopathy, chest pain or shortness of breath with activity, stroke, TIA, or those with 3 or more risk factors for ischemic coronary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Eczema/exfoliative skin conditions: <b> [US Boxed Warning]: Following vaccination, eczema vaccinatum has been reported. Patients with eczema, a history of eczema, or other acute or chronic exfoliative skin conditions may be at an increased risk for severe skin infections;</b> these patients should not be vaccinated in nonemergency situations, including laboratory and health care personnel at risk for occupational exposure to orthopoxviruses (ACIP [Petersen 2015]; CDC/ACIP [Wharton 2003]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP generally recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible (ACIP [Kroger 2017]). For smallpox vaccine: May be given simultaneously with any inactive and most live vaccines. Varicella vaccine should be administered at least 4 weeks before or after smallpox vaccine, to help interpret any postvaccination rashes that may arise. Tuberculosis screening (PPD skin test) should be administered &ge;1 month after smallpox vaccination, to avoid temporary false-negative test results.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: <b>[US Boxed Warning]: Patients with congenital or acquired immune deficiency disorders (including those on immunosuppressive medications) are at increased risk for severe adverse reactions.</b> Use in patients with severe immune deficiency may result in progressive vaccinia and is, therefore, contraindicated by the manufacturer. The ACIP recommends that these patients not be vaccinated in nonemergency situations. In general, live vaccines should be administered &ge;4 weeks prior to planned immunosuppression and avoided within 2 weeks of immunosuppression when feasible; live vaccines should not be administered for at least 3 months after immunosuppressive therapy (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Safety and efficacy have not been established for use in children &lt;16 years of age; recommendations are based on previously available vaccine. <b>[US Boxed Warning]: Infants &lt;12 months of age may be at increased risk for severe adverse reactions.</b> Per the ACIP, vaccine is contraindicated for use in infants &lt;12 months of age (nonemergency situation) and use is not recommended in pediatric patients &lt;18 years of age (nonemergency situations) (ACIP [Petersen 2015]; CDC/ACIP [Wharton 2003]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Pregnant women are at increased risk for severe adverse reactions and should not be vaccinated in nonemergency situations.</b> <i>In utero</i> transmission of virus has been observed; fetal vaccinia and fetal death have occurred. Pregnant women should be warned about the possibility of inadvertent transmission of vaccinia virus from others who have recently been vaccinated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Some dosage forms may contain human albumin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neomycin: Products may contain neomycin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polymyxin B: Products may contain polymyxin B.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biohazard: Use appropriate precautions for handling and disposal. Personnel responsible for preparation and administration should observe appropriate contact precautions to avoid inadvertent inoculation (eg, wear surgical or protective gloves and avoid contact of vaccine with skin, eyes, or mucous membranes). Dispose of all materials for preparation and administration in a biohazard waste container. All materials must be burned, boiled, or autoclaved. Vaccinees should change bandages away from others and launder their own linens separately to prevent transmission.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: For percutaneous administration only. Vaccination is given by scarification (multiple punctures into superficial layers of the skin) only. <b>Not for IM, IV, or SubQ injection.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: The risk of vaccination complications must be weighed against the risk of experiencing a potentially fatal smallpox infection.</b> Patients at greatest risk for adverse reactions from the vaccine are also at increased risk for death from smallpox infection. Recommendations for use in response to bioterrorism are periodically updated by the CDC, and may be found at www.cdc.gov.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood and organ donation: Patients should be advised not to donate blood or organs for 21 to 30 days following vaccination or until the scab has separated; contacts who have inadvertently contracted vaccinia should avoid donating blood for 14 days (CDC/ACIP [Wharton 2003]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transmission of virus: <b>[US Boxed Warning]: Live vaccinia virus may be transmitted to close contacts of the vaccinee; risks for the close contact are the same as those receiving the vaccine.</b> Virus may be cultured from vaccination sites until scab separates from lesion; viral shedding ceases once the lesion is re-epithelialized (~14 to 21 days after vaccination). Individuals should be instructed to avoid contact with patients at high risk of transmission/adverse effects, including breastfeeding women and patients with eczema or immunodeficiency during this time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300047\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221439\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10175&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Axicabtagene Ciloleucel: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Axicabtagene Ciloleucel may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live virus vaccines for at least 6 weeks prior to initiation of lymphodepleting therapy, during axicabtagene ciloleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live). AzaTHIOprine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose azathioprine (3 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of azathioprine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclizumab: May enhance the adverse/toxic effect of Vaccines (Live). Daclizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethyl Fumarate: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live). Management: Canadian labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment.  U.S. labeling does not mention this.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dupilumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinal infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<b> Exceptions: </b>AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone (Systemic); Budesonide (Systemic); Corticotropin; Cortisone; Cytarabine (Liposomal); Deflazacort; Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live). Leflunomide may diminish the therapeutic effect of Vaccines (Live). Management: The ACIP guidelines state that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy. However, the ACR does not recommend avoiding live vaccines in patients being treated with leflunomide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live). Mercaptopurine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose 6-mercaptopurine (1.5 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of mercaptopurine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live). Methotrexate may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose methotrexate (0.4 mg/kg/week or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses of methotrexate should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the adverse/toxic effect of Vaccines (Live). Ocrelizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rabies Immune Globulin (Human): May diminish the therapeutic effect of Vaccines (Live). Management: Avoid administering the measles vaccine within 4 months after administration of rabies immune globulin. Avoid administering other live vaccines within 3 months after administration of rabies immune globulin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Tisagenlecleucel may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live virus vaccines for two weeks prior to initiation of lymphodepleting therapy, during tisagenlecleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): May diminish the therapeutic effect of other Vaccines (Live). Management: Two or more injectable or nasally administered live vaccines not administered on the same day should be separated by at least 28 days (ie, 4 weeks). If not, the vaccine administered second should be repeated at least 4 week later.<b> Exceptions: </b>Adenovirus (Types 4, 7) Vaccine; Cholera Vaccine; Rotavirus Vaccine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus Vaccine: Smallpox Vaccine Live may enhance the adverse/toxic effect of Varicella Virus Vaccine. It may be difficult to determine which vaccine caused skin lesions or other adverse effects. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May enhance the adverse/toxic effect of Vaccines (Live). Venetoclax may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live, attenuated vaccines before, during, or after (prior to B-cell recovery) venetoclax treatment.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221441\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221453\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Pregnant women are at increased risk for severe adverse reactions.</b> Animal reproduction studies have not been conducted with this vaccine. Vaccinia vaccine has not been associated with the development of congenital malformations. On rare occasions, vaccination has been reported to cause fetal infection. Fetal vaccinia infection was associated with stillbirth or neonatal mortality. According to the CDC, vaccination of pregnant women is contraindicated in a pre-event setting, including laboratory and health care personnel at risk for occupational exposure to orthopoxviruses (ACIP [Petersen 2016]; CDC/ACIP [Wharton 2003]); vaccination is recommended in the post-event setting, unless a relative contraindication exists (CDC [Petersen 2015]). Pregnancy should be avoided for at least 4 weeks following vaccination. Health care providers may enroll pregnant women who were inadvertently vaccinated during pregnancy (or who were a close contact of a vaccinee within the previous 4 weeks of vaccination) in the CDC pregnancy registry by calling 404-639-8253 or 877-554-4625 (CDC/ACIP [Wharton 2003]). All civilian and military cases should be reported to the Department of Defense.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221454\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Excretion of the vaccine virus or antibodies into breast milk is not known. According to the CDC, vaccination of a breastfeeding woman is contraindicated in a nonemergency situation situation including laboratory and health care personnel at risk for occupational exposure to orthopoxviruses (CDC/ACIP [Wharton 2003]); vaccination is recommended in the postevent setting, unless a relative contraindication exists (CDC [Petersen 2015]). Breastfeeding should be interrupted if the vaccine is administered in an emergency situation. Breastfeeding women should take precautions to avoid inadvertent contact with a vaccinee. One case of tertiary transfer to an infant has been reported following secondary transfer to a breastfeeding woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221442\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Observe for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primary vaccines: Monitor vaccination site; inspect after 6 to 8 days. Evidence of a major reaction (vesicular or pustular lesion or an area of palpable induration surrounding a central lesion) confirms success of vaccination. An equivocal reaction (all responses other than a major reaction) requires revaccination in patients undergoing primary vaccination only.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Revaccination: Successful vaccination is confirmed when a major cutaneous reaction is observed 6 to 8 days postvaccination. Prior vaccinations may reduce the cutaneous response and does not necessarily indicate a vaccination failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221434\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccinia virus is similar in some respects to the variola (smallpox) virus. By inducing a localized infection with vaccinia virus, immunity to both vaccinia and variola is achieved. Vaccination results in viral replication, production of neutralizing antibodies, immunity, and cellular hypersensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efficacy: Neutralizing or hemagglutination-inhibiting antibodies against vaccinia develop in more than 95% of individuals after primary vaccination and may be boosted on revaccination (CDC/ACIP [Rotz 2001]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221449\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Neutralizing antibodies appear 15-20 days after vaccination; time to appearance of neutralizing antibodies may be shorter (~7 days) following revaccination (CDC/ACIP [Rotz 2001]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: For 75% of patients, neutralizing antibody titers (&gt;1:10) persisted for 10 years after receiving second doses and &lt;30 years after receiving 3 doses of vaccine (CDC/ACIP [Rotz 2001]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49939506\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>ACAM2000 (AU);</li>\n      <li>En Zai Shi (CN);</li>\n      <li>Imvanex (CZ, DE, DK, EE, LT, LV, MT, PL, PT, SK);</li>\n      <li>Ospavir (RU);</li>\n      <li>TEOVac (RU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACAM2000 (smallpox vaccine) [prescribing information]. Cambridge, MA: Sanofi Pasteur Biologics; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blendon RJ, DesRoches CM, Benson JM, et al, &ldquo;The Public and the Smallpox Threat,&rdquo; <i>N Engl J Med</i>, 2003, 348(5):426-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/12496352/pubmed\" target=\"_blank\" id=\"12496352\">12496352</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bozzette SA, Boer R, Bhatnagar V, et al, &ldquo;A Model for a Smallpox-Vaccination Policy,&rdquo; <i>N Engl J Med</i>, 2003, 348(5):416-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/12496353/pubmed\" target=\"_blank\" id=\"12496353\">12496353</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Secondary and Tertiary Transfer of Vaccinia Virus Among U.S. Military Personnel, United States and Worldwide, 2002-2004,&rdquo; <i>MMWR</i>, 2004, 53(5):103-5. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5305a3.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5305a3.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/14961003/pubmed\" target=\"_blank\" id=\"14961003\">14961003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cono J, Casey CG, Bell DM, et al, &ldquo;Smallpox Vaccination and Adverse Reactions. Guidance for Clinicians,&rdquo; <i>MMWR Recomm Rep</i>, 2003, 52(RR-4):1-28.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eckart RE, Love SS, Atwood JE, et al, &ldquo;Incidence and Follow-up of Inflammatory Cardiac Complications After Smallpox Vaccination,&rdquo; <i>J Am Coll Cardiol</i>, 2004, 44(1):201-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/15234435/pubmed\" target=\"_blank\" id=\"15234435\">15234435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parrino J and Graham BS, &ldquo;Smallpox Vaccines: Past, Present , and Future,&rdquo; <i>J Allergy Clin Immunol</i>, 2006, 118(6):1320-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/17157663/pubmed\" target=\"_blank\" id=\"17157663\">17157663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petersen BW, Damon IK, Pertowski CA, et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. <i>MMWR Recomm Rep</i>. 2015;64(RR-2):1-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/25695372/pubmed\" target=\"_blank\" id=\"25695372\">25695372</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petersen BW, Harms TJ, Reynolds MG, Harrison LH. Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses - Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. <i>MMWR Morb Mortal Wkly Rep</i>. 2016;65(10):257-62. doi: 10.15585/mmwr.mm6510a2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/26985679/pubmed\" target=\"_blank\" id=\"26985679\">26985679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rotz LD, Dotson DA, Damon IK, et al. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. <i>MMWR Recomm Rep</i>. 2001;50(RR-10):1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/15580803/pubmed\" target=\"_blank\" id=\"15580803\">15580803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sepkowitz KA, &ldquo;How Contagious is Vaccinia?&rdquo; <i>N Engl J Med</i>, 2003, 348(5):439-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/12496351/pubmed\" target=\"_blank\" id=\"12496351\">12496351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Smallpox Vaccine,&rdquo; <i>Med Lett Drugs Ther</i>, 2003, 45(1147):1-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/12515951/pubmed\" target=\"_blank\" id=\"12515951\">12515951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wharton M, Strikas RA, Harpaz R, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). <i>MMWR</i>. 2003;52(RR-07):1-16. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5207a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5207a1.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information/abstract-text/12710832/pubmed\" target=\"_blank\" id=\"12710832\">12710832</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10175 Version 101.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709414\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F221461\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F221473\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F221463\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990104\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987393\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F221470\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51160184\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51160185\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062221\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F221445\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F221432\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11234330\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874989\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F221447\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F221446\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F221437\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F221450\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F221435\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300047\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F221439\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F221441\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F221453\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F221454\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F221442\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F221434\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F221449\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49939506\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10175|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-patient-drug-information\" class=\"drug drug_patient\">Smallpox vaccine (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department): Patient drug information</a></li></ul></div></div>","javascript":null}